similarity has led to the speculation that pHN61 could replicate in A. pleuropneumoniae. We tested this by electrotransformation of A. pleuropneumoniae 4074 with pHN61 as described above. In this transformant, the MICs of lincomycin and clindamycin increased from 16 to 128 mg/L and 4 to 64 mg/L respectively, whereas the MIC of erythromycin was unchanged (1 mg/L). The presence of pHN61 was verified by plasmid extraction and Southern blot hybridization. These results indicate the possibility of pHN61 circulating between strains of H. parasuis and A. pleuropneumoniae.
Sir, To date, fluoroquinolone resistance in meningococci has been reported only rarely and never from the African continent. Sporadic cases of low-level (MIC ≤0.25 mg/L) ciprofloxacin-resistant Neisseria meningitidis have been reported from France (1999), Australia (2000) , Argentina (2002) , Spain (2003) and Hong Kong (2006) . 1 -5 In India, decreased susceptibility to ciprofloxacin emerged during a serogroup A outbreak in 2005 -06 (MIC range ¼ 0.125 -0.5 mg/L). 6 A cluster of genetically related ciprofloxacin-resistant (MIC ¼ 0.25 mg/L) serogroup B cases occurred in 2007 -08 in the North Dakota/Minnesota region in the USA. 7 Public health authorities immediately terminated the use of chemoprophylactic ciprofloxacin in that region.
In 2009, an HIV-positive Zimbabwean female, who had travelled to South Africa 1 week earlier, was diagnosed with acute meningitis. She was admitted to a Johannesburg hospital with symptoms of headache and confusion, and N. meningitidis was cultured from the CSF. The patient was treated with ceftriaxone resulting in a favourable clinical outcome and was discharged 2 weeks later. She shared an apartment in the inner city at the time; however, no other cases were reported from close contacts or individuals living in the same building or neighbourhood. History of prior antibiotic exposure was unknown as the patient returned to Zimbabwe before additional follow-up information could be obtained.
We received the isolate as part of national laboratory-based surveillance for invasive meningococcal disease. The isolate was confirmed as serogroup W135 by slide agglutination with polyclonal antisera to capsular polysaccharides A, C, X, Y, Z and W135, and monoclonal antibody to capsular polysaccharide B (Remel Biotech Ltd, Dartford, UK). Susceptibility testing was performed using the CLSI guidelines 8 using both disc screening and MIC determination by Etest w (AB Biodisk, Solna, Sweden). The isolate was susceptible to chloramphenicol (≤0.5 mg/L), rifampicin (≤0.5 mg/L), penicillin (≤0.03 mg/L) and ceftriaxone (≤0.002 mg/L) and resistant to nalidixic acid (12 mg/L) and ciprofloxacin (0.125 mg/L). Fluoroquinolone MICs were repeated by broth microdilution and yielded identical results to Etest w , namely 0.125 mg/L for ciprofloxacin and levofloxacin, and 0.25 mg/L for ofloxacin. Nitrocefin (Oxoid Ltd, Basingstoke, UK) was used to exclude b-lactamase production.
Since 2000, all isolates received through our surveillance programme have been routinely screened for fluoroquinolone non-susceptibility using ofloxacin discs and breakpoints stipulated for Neisseria gonorrhoeae. 9 In 2005, we commenced using CLSI breakpoints for N. meningitidis. 10 Prior to the case reported in 2009, no resistance to fluoroquinolones had been reported in South Africa, 11 nor has it been found subsequently. Multilocus sequence typing characterized the strain as ST-11 of the ST-11/ET-37 clonal complex. The quinolone resistance determining regions (QRDRs) of the gyrA and parC loci were sequenced and compared with analogous regions of resistant and susceptible meningococcal and Neisseria lactamica strains, for which sequence data are available in GenBank. GyrA of the South African isolate harboured two substitutions; Leu-30 Phe and Thr-91 Ile. No changes were observed in the QRDR of ParC. gyrA showed 99% nucleotide similarity when compared with meningococcal strains MC58 (AE002098) and FAM18 (AM421808) and ciprofloxacin-resistant strains from China (CP000381) and California (EU780518). In contrast, the South African isolate shared less sequence identity (94%) with gyrA of N. lactamica and the North Dakota/Minnesota meningococcal strains.
12
With the exception of the Hong Kong and an Argentinian case, which were attributed to efflux, reduced susceptibility to ciprofloxacin in other reported cases was caused by point mutations in the QRDR of gyrA. The Thr-91 Ile substitution in GyrA of the South African isolate is common in isolates from other geographical regions, and has been confirmed to be associated with fluoroquinolone resistance in N. meninigitidis, N. gonorrhoeae and Escherichia coli. Sequence analysis of gyrA and parC from a selection of laboratory-generated quinolone-resistant mutants, for which MICs ranged from 0.016 to 16 mg/L, showed that resistance was initiated by a single mutation appearing in GyrA, usually at amino acid position 91 (Thr Ile/Ala). 13 Additional increases in MIC (≥2 mg/L) were mostly associated with an additional change in GyrA (Asp-95 Asn) coupled with a single ParC substitution. In contrast, ciprofloxacin-resistant isolates from the South Dakota/Minnesota study showed strong evidence of having acquired resistance through horizontal gene transfer with N. lactamica.
12 DNA sequence alignment confirmed that the substitutions in the South African strain appear to have arisen by point mutation. Apart from Thr-91 Ile, the South African strain harboured one additional change in the QRDR of GyrA. The role of this mutation in contributing to reduced susceptibility is unknown as a substitution at this position has not previously been reported in any other strains; however, the relatively low MIC seems to indicate that resistance may be solely due to the Thr-91 Ala substitution.
The emergence of strains with reduced susceptibility to fluoroquinolones may have implications for carriage eradication following exposure and therefore continued surveillance is necessary to monitor any increase in the prevalence of such strains. 
